Clinical Trial

Nutritional Supplement for Treating Chemotherapy Induced Neuropathy

Completed Phase 4
View on ClinicalTrials.gov →
Summary
Administration of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin B12, vitamin B6 , vitamin B1, nicotinamide, magnesium, zinc, vitamin E, and superoxide of dismutase in individuals receiving chemotherapy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-08; most recent amendment 2025-12-19.
Trial Details
NCT Number NCT07022938
Lead Sponsor Aristotle University Of Thessaloniki
Conditions Cancer, Neuropathy, Chemotherapy Induced Pain Neuropathy, Chemotherapy-Induced Peripheral Neuropathy
Enrollment 71 participants
Start Date 2021-11-01
Primary Completion 2025-01-31 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-26